Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Fall from Grace of Peregrine Pharmaceuticals

Published: Wednesday, October 17, 2012
Last Updated: Wednesday, October 17, 2012
Bookmark and Share
On September 24, 2012, the company announced the discovery of ‘major data discrepancies’ between reported results and patient treatment code assignments.

The discrepancies relate to their randomized, double-blind, Phase IIb clinical trial investigating bavituximab as second-line treatment in stage IIIb and IV Non-Small Cell Lung Cancer (NSCLC) patients.

Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is believed to trigger vascular disruption, and enhance antitumor and antiviral immune responses.

Last month, the company had revealed exciting interim data suggesting patients in the treatment arm of the study receiving bavituximab and docetaxel had a median Overall Survival (OS) of 12.1 months compared with 5.6 months in patients treated with docetaxel alone.

Given the magnitude of the apparent success of this drug in terms of median OS, the trial raised a few eyebrows as to its legitimacy. Half of the patients enrolled were from Eastern Europe and India with no clear geographic breakdown, so racial disparities as well as regional clinical trial standards cannot be accounted for.

As many biotech devotees will remember, previous unrelated studies conducted in Eastern Europe disappointed shareholders after showing distinctly positive results that could not be subsequently repeated in US trials, a la Medivation’s Dimebon.

For Peregrine followers, the high survival rates and ex-US cohort draws into question whether patients were appropriately categorized as late-stage second-line NSCLC patients across all geographies, or whether their classification as having failed first-line treatment is ambiguous.

Peregrine’s warning to shareholders to disregard the data due to disparities proves their own lack of faith in the trial results.

Peregrine asserted the issue is specific to this clinical trial and will not impact other ongoing bavituximab trials; however, the company’s credibility has been drawn into question before.

In March 2012, Peregrine presented data from a clinical trial for first-line use of bavituximab in locally-advanced or metastatic NSCLC patients.

The results were later independently reviewed and determined to be unexpectedly high in Progression-Free Survival (PFS) in lung cancer patients receiving standard chemotherapy.

Peregrine admitted to results being skewed by principle investigator bias rather than drug inefficacy or fraudulent reporting but this did not fare well for their reputation, as was demonstrated in the dip in share price at the time.

Data discrepancies like these are raising concerns, and the trend of unfounded positive results shown in the treatment arms of trials is alarming.

The company is trying to salvage data from the most recent trial, but this deluge of shifting information has investors losing faith in bavituximab’s potential to progress to Phase III of clinical development, as well as Peregrine’s ability to conduct clinical trials. This is clearly reflected in the sharp fall of the firm’s stock price to $0.86 from its 52-week high of $5.50.

Peregrine Pharmaceuticals’ commercial viability and future development of its pipeline products is now at risk. The company’s creditors, Silicon Valley Bank, Oxford Finance, and MidCap Financial, filed a default on a loan of $30m which was underwritten a week prior to the release of initial positive results for bavituximab.

The loan was issued pending positive results from the Phase IIb study and has since been recalled after Peregrine deemed the trial success unsubstantiated. Law offices of Howard G. Smith are also investigating the company, citing possible violations of federal securities laws.

With the current turn of events, it is unlikely bavituximab will ever see Phase III clinical trials. Due to these financial constraints at Peregrine, the company only has enough money to fund operations until April 2013.

With bankruptcy looming, Peregrine Pharmaceuticals needs to address any trial data discrepancies as a matter of urgency, identify the root cause of this issue and further communicate its impact on bavituximab results.

The company is obligated to clarify to shareholders the error made by the third party commissioned with coding the treatment arms, admit where the responsibility lies, communicate any positive data from the interim results of other Phase II trials of bavituximab, and present the corrected results for the Phase II trial in question.

Cotara, the company’s second oncology pipeline product, is based on proprietary technology and has demonstrated to increase OS in patients based on interim results from Phase II studies.

Peregrine could package the two products into a portfolio to entice investors or a pharmaceutical company as a possible acquisition target.

The entire pharmaceutical industry can learn from the failures of Peregrine in presenting results prematurely. The company is now facing a bleak future of either bankruptcy or acquisition. Those investors who were initially bullish from the positive trial results have since concluded the clinical data to be invalid and have, more notably, lost faith in the integrity of the company.

Investors should await clarification of the results from Peregrine Pharmaceuticals and closely monitor the company’s next moves before deciding the fate of the company.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Big R&D Investment Trend as Mid-Cap Biotechs Push to Get Drugs to Market
20% of overall increase in R&D expenditure in just a year.
Thursday, March 07, 2013
T-DM1 Demonstrates Overall Survival Benefit in Metastatic Breast Cancer
Next target, FDA approval.
Thursday, August 30, 2012
Tofacitinib: Sacrificing Safety for Novelty?
FDA has extended the review period of tofacitinib by three months.
Wednesday, August 22, 2012
Poor Healthcare Policies and Infrastructure, But India’s Pharma Market Continues to Boom
Country’s pharmaceutical industry continue to expand rapidly in the coming years.
Tuesday, August 21, 2012
Aplastic Anemia Patients in Need of New Treatment Options
New study explores the failings of current treatment options for aplastic anemia.
Friday, February 24, 2012
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!